The Arbutus Biopharma Corporation (ABUS) announced today that it has entered into a multi-year clinical development agreement with a large pharmaceutical company.  The agreement is subject to court approval.  According to the SEC's complaint filed in the U.S. District Court for the Southern District of New York, Arbutus Biopharma has failed to identify a cure for hepatitis B.  The SEC's complaint alleges that Arbutus violated the antifraud provisions of Section 17(a) of the Securities Act of 1933 ("Securities Act") and Section 10(b) of the Securities Exchange Act of 1934 ("Exchange Act") and Rule 10b-5 thereunder.  Without admitting or denying the allegations in the complaint, Arbutus has agreed to the terms of the agreement.  The settlement is subject to court approval.  The SEC's complaint, filed in federal court in New York, charges Arbutus with violating Section 17(a) of the Securities Act and Section 10(b) of the Exchange Act and Rule 10b-5 thereunder, and seeks disgorgement of ill-gotten gains plus interest, penalties, and injunctive relief.  The settlement is subject to court approval by the court.  The SEC's investigation was conducted by Mayank Mamtani and was supervised by Bill Collier.  The SEC appreciates the assistance of the U.S. Attorney's Office for the Southern District of New York, the Federal Bureau of Investigation, and the U.S. Secret Service.  The SEC's Office of Investor Education and Advocacy has issued anÂ Investor AlertÂ to encourage investors to check the background of anyone selling or offering them an investment using the free and simple search tool onÂ Investor.gov.